Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CAPTN-3
    •     IM1240
    •     IM1305
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Author: Yaell Purple

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CAPTN-3
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech to Present IM1240 in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 at 15:00 CET in Barcelona, Spain.
  • Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.
  • Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
  • Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
  • CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
  • Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
  • CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
  • Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
  • APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
  • NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
Purple Biotech to Present IM1240 in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 at 15:00 CET in Barcelona, Spain.

Purple Biotech to Present IM1240 in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 at 15:00 CET in Barcelona, Spain.

By PurpleDev1
in
Events
Nov 01, 2026
Read more
Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.

Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.

By PurpleDev1
in
Events
Jun 16, 2026
Read more

Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window

By PurpleDev1
in
CAPTN-3
Publications
Jun 11, 2026

Presented at the EACR 2026 Congress, June, 2026

Read more
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.

By PurpleDev1
in
Events
Dec 22, 2025
Read more

CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers

By PurpleDev1
in
CAPTN-3
Publications
Dec 11, 2025

Presented at the ESMO Immuno-Oncology Congress 2025, December, 2025

Read more
Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.

Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.

By PurpleDev1
in
Events
Aug 27, 2025
Read more

CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers

By PurpleDev1
in
CAPTN-3
Publications
Jun 23, 2025

Presented at the EACR 2025 Congress, June, 2025

Read more
Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup

Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup

By PurpleDev1
in
CM-24
Publications
May 01, 2025

Presented at the AACR annual meeting, April 2025

Read more

APC-loss as a potential biomarker for NT219 treatment in colorectal cancer

By PurpleDev1
in
NT-219
Publications
Apr 29, 2025

Presented at the AACR annual meeting, April 2025

Read more

NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)

By PurpleDev1
in
NT-219
Publications
Apr 29, 2025

Presented at the AACR annual meeting, April 2025

Read more
1 2 3 4 Next »
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2026 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset
We utilize cookies to improve our site and your experience when using it. To find more details, and to know how we obtain, store, and work with your personal data, check our Privacy Policy page.
You can revoke your consent any time using the Revoke consent button.